BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004;19:541-546. [PMID: 15308845 DOI: 10.3346/jkms.2004.19.4.541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18:e212-e216. [PMID: 21692935 DOI: 10.1111/j.1365-2893.2011.01435.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
2 Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007;79:1650-4. [PMID: 17854040 DOI: 10.1002/jmv.20974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
3 Ou ZY, Liu N, Chen CJ, Cheng G, He YS. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J Clin Microbiol 2005;43:5685-9. [PMID: 16272505 DOI: 10.1128/JCM.43.11.5685-5689.2005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Umeoka F, Iwasaki Y, Matsumura M, Takaki A, Kobashi H, Tatsukawa M, Shiraha H, Fujioka S, Sakaguchi K, Shiratori Y. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701. [PMID: 16933008 DOI: 10.1007/s00535-006-1834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
5 Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 2012;84:217-222. [PMID: 22170540 DOI: 10.1002/jmv.23191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Xu G, You Q, Pickerill S, Zhong H, Wang H, Shi J, Luo Y, You P, Kong H, Lu F, Hu L. Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine. J Med Virol 2010;82:1143-9. [DOI: 10.1002/jmv.21811] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
7 Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. Korean J Hepatol 2008;14:503-12. [PMID: 19119245 DOI: 10.3350/kjhep.2008.14.4.503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32:1535-1542. [PMID: 22882650 DOI: 10.1111/j.1478-3231.2012.02859.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
9 Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis. 2008;12:83-87. [PMID: 17698384 DOI: 10.1016/j.ijid.2007.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
11 Kim DH, Kang HS, Hur SS, Sim S, Ahn SH, Park YK, Park ES, Lee AR, Park S, Kwon SY, Lee JH, Kim KH. Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray. Gut Liver 2018;12:331-41. [PMID: 29271185 DOI: 10.5009/gnl17336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Tan YW, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis 2012;16:250-5. [PMID: 22729192 [PMID: 22729192 DOI: 10.1016/s1413-8670(12)70319-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
13 Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
14 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
15 Hassan AMS, Abo El-Ela FI, Abdel-Aziz AM. Investigating the potential protective effects of natural product quercetin against imidacloprid-induced biochemical toxicity and DNA damage in adults rats. Toxicol Rep 2019;6:727-35. [PMID: 31388500 DOI: 10.1016/j.toxrep.2019.07.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Tan YW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. World J Gastroenterol 2015; 21(7): 2089-2095 [PMID: 25717242 DOI: 10.3748/wjg.v21.i7.2089] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
17 Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, Aghakhani A. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. Int J Infect Dis. 2008;12:252-255. [PMID: 17954033 DOI: 10.1016/j.ijid.2007.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
18 Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21:1783-1788. [PMID: 17074014 DOI: 10.1111/j.1440-1746.2006.04567.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
20 Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 18.0] [Reference Citation Analysis]